SpringWorks Therapeutics, Inc.
🏢 View company profile →41Patents
41Active
41Granted
68Portfolio score
Filing activity: Feb 17, 2021 → Oct 10, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11427534B1 | Solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof | Chemistry; Metallurgy | 16 | Active |
| US11084780B1 | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | Chemistry; Metallurgy | 11 | Active |
| US11806321B2 | Non-linear dosing of mirdametinib | Human Necessities | 8 | Active |
| US11872211B2 | Treatments with nirogacestat | Human Necessities | 7 | Active |
| US11819487B2 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | Human Necessities | 6 | Active |
| US11571402B2 | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | Human Necessities | 5 | Active |
| US11806322B2 | Mirdametinib treatment | Human Necessities | 4 | Active |
| US11938116B2 | Treatments with nirogacestat | Human Necessities | 3 | Active |
| US11925619B2 | Treatments with nirogacestat | Human Necessities | 3 | Active |
| US11957662B2 | Treatments with nirogacestat | Human Necessities | 3 | Active |
| US11925620B1 | Treatments with nirogacestat | Human Necessities | 3 | Active |
| US11951096B2 | Treatments with nirogacestat | Human Necessities | 3 | Active |
| US12029711B1 | Dosage forms of mirdametinib | Human Necessities | 3 | Active |
| US11883375B2 | Mirdametinib treatment | Human Necessities | 2 | Active |
| US12011424B2 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | Human Necessities | 2 | Active |
| US11884610B2 | Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US11839595B2 | Mirdametinib treatment | Human Necessities | 2 | Active |
| US12090128B2 | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof | Human Necessities | 1 | Active |
| US11807611B2 | Chlorinated tetralin compounds and pharmaceutical compositions | Chemistry; Metallurgy | 1 | Active |
| US11612588B1 | Chlorinated tetralin compounds and pharmaceutical compositions | Chemistry; Metallurgy | 1 | Active |
| US11844780B2 | Chlorinated tetralin compounds and pharmaceutical compositions | Chemistry; Metallurgy | 1 | Active |
| US12247012B2 | Synthesis of nirogacestat | Chemistry; Metallurgy | 0 | Active |
| US12036207B2 | Treatments with nirogacestat | Human Necessities | 0 | Active |
| US12030866B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | Chemistry; Metallurgy | 0 | Active |
| US11780800B1 | Fluorinated phenylamino compounds and pharmaceutical compositions | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.